PI-RADS v2.1: moving towards clarity (comments on the updated version)

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2020-07-21 DOI:10.17650/1726-9776-2020-16-2-15-28

N. Rubtsova, A. Mishchenko, V. Danilov, G. A. Gulin, B. Alekseev, А. Kaprin

{"title":"PI-RADS v2.1: moving towards clarity (comments on the updated version)","authors":"N. Rubtsova, A. Mishchenko, V. Danilov, G. A. Gulin, B. Alekseev, А. Kaprin","doi":"10.17650/1726-9776-2020-16-2-15-28","DOIUrl":null,"url":null,"abstract":"Previously presented Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) system was developed on the basis of consensus that was achieved by the results of published studies containing expert and analytical conclusions. Numerous studies on PI-RADS v2, not only confirmed the importance of a unified system in the diagnosis of prostate cancer, but also revealed a number of limitations. In order to eliminate flaws of PI-RADS v2, a number of potential solutions were proposed. The PI-RADS Steering Committee recommended changes in PI-RADS v2, with maintaining the structure of sequence scoring and using these scores to obtain the final category. The updated version was published as PI-RADS v2.1 at the beginning of 2019. It is expected that the use of PI-RADS v2.1 will optimize and simplify the evaluation magnetic resonance imaging of prostate and reduce the number of interpretation errors. At the same time, it is necessary to continue further studies on the assessment of the clinical significance of this system when choosing a treatment strategy and monitoring patients with a high potentialfor the development","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"16 1","pages":"15-28"},"PeriodicalIF":0.1000,"publicationDate":"2020-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2020-16-2-15-28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Previously presented Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) system was developed on the basis of consensus that was achieved by the results of published studies containing expert and analytical conclusions. Numerous studies on PI-RADS v2, not only confirmed the importance of a unified system in the diagnosis of prostate cancer, but also revealed a number of limitations. In order to eliminate flaws of PI-RADS v2, a number of potential solutions were proposed. The PI-RADS Steering Committee recommended changes in PI-RADS v2, with maintaining the structure of sequence scoring and using these scores to obtain the final category. The updated version was published as PI-RADS v2.1 at the beginning of 2019. It is expected that the use of PI-RADS v2.1 will optimize and simplify the evaluation magnetic resonance imaging of prostate and reduce the number of interpretation errors. At the same time, it is necessary to continue further studies on the assessment of the clinical significance of this system when choosing a treatment strategy and monitoring patients with a high potentialfor the development

查看原文本刊更多论文

PI-RADS v2.1:走向清晰(对更新版本的评论)

先前提出的前列腺成像报告和数据系统第2版(PI-RADS v2)系统是在包含专家和分析结论的已发表研究结果达成共识的基础上开发的。大量关于PI-RADS v2的研究，不仅证实了一个统一的系统在前列腺癌诊断中的重要性，同时也揭示了一些局限性。为了消除PI-RADS v2的缺陷，提出了一些可能的解决方案。PI-RADS指导委员会建议对PI-RADS v2进行修改，保持序列评分的结构，并使用这些分数来获得最终的类别。更新版本于2019年初发布为PI-RADS v2.1。预计PI-RADS v2.1的使用将优化和简化前列腺磁共振成像的评估，减少判读错误的数量。同时，在选择治疗策略和监测具有较高发展潜力的患者时，有必要继续深入研究评估该系统的临床意义

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.